Breaking News

Evonik Launches Combo Polymer for Enteric Coatings

EUDRAGIT FL 30 D-55 enables plasticizer-free formulations, making it ideal for the compression of coated multiparticulates

By: Kristin Brooks

Managing Editor, Contract Pharma

Evonik, a provider of excipients used in oral solid dosage forms, has launched an advanced combination polymer for enteric coatings. EUDRAGIT FL 30 D-55 leverages Evonik’s new AEMP technology (Advanced Excipient Manufacturing Process) to combine the respective benefits of two well-established and monographed polymers including EUDRAGIT L 30 D-55. 

According to the company, EUDRAGIT FL 30 D-55 is a highly flexible polymer that enables plasticizer-free formulations, making it ideal for the compression of coated multiparticulates, and can be sprayed with a smooth, fast and no-stick process for excellent adhesion. As a single product, the company says spray suspension preparation times can be reduced by up to 70%, while lowering manufacturing costs and total required polymer volumes. It has also been shown to reduce coating film thicknesses, creating opportunities for increased drug loading.

“As the first ever excipient based upon our proprietary AEMP® technology, EUDRAGIT FL 30 D-55 combines the best features of two well-accepted polymers including EUDRAGIT L 30 D-55, which has been the gold standard for enteric coatings for decades,” said Paul Spencer, Global Head of Oral Drug Delivery Solutions for the Health Care business line of Evonik. “This high-tech excipient features extremely high flexibility even without plasticizers. EUDRAGIT FL 30 D-55 sets a new standard for enteric coatings to help customers reduce processing complexity, lower preparation times and save costs.” 

Companies seeking more information about EUDRAGIT® FL 30 D-55 can visit the Evonik booth 9K20 at CPhI Worldwide in Madrid from October 9 to 11, or AAPS PharmSci 360 in Washington D.C. at booth 2127. Requests for individual meetings or product samples can be made via healthcare@evonik.com.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters